Last reviewed · How we verify

Malaria Prevention — Treatment Landscape & Competitive Intelligence

Malaria Prevention (disease) competitive landscape: 4 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

4 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Malaria Prevention, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Hydroxychloroquine Sulfate HYDROXYCHLOROQUINE Advanz Antimalarial Toll-like receptor 9 1955-01-01
Aralen CHLOROQUINE Sanofi Antimalarial Sigma non-opioid intracellular receptor 1 1949-01-01
Hydroxychloroquin Hydroxychloroquin Children's Hospital of Fudan University Transmembrane protein 97, Alpha-1D adrenergic receptor, Alpha-2A adrenergic receptor
Hydroxychloroquine Sulfate hydroxychloroquine-pill Sanofi Antimalarial Toll-like receptor 9 1955-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Sanofi · 2 drugs in Malaria Prevention
  2. Advanz · 1 drug in Malaria Prevention
  3. Children's Hospital of Fudan University · 1 drug in Malaria Prevention

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Malaria Prevention:

Cite this brief

Drug Landscape (2026). Malaria Prevention — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/malaria-prevention. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing